Acid Stripping of Surface IgE Antibodies Bound to FcεRI is Unsuitable for the Functional Assays that Require Long-Term Culture of Basophils and Entire Removal of Surface IgE.

CD123 IL-3 IgE acetic acid activation allergy atopy basophil human inflammation lactic acid stripping viability

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
13 Jan 2020
Historique:
received: 22 12 2019
accepted: 10 01 2020
entrez: 17 1 2020
pubmed: 17 1 2020
medline: 2 10 2020
Statut: epublish

Résumé

Basophils are rare granulocytes and dysregulated functions of these cells are associated with several atopic and non-atopic allergic diseases of skin, respiratory system and gastrointestinal tract. Both cytokines and immunoglobulin E (IgE) are implicated in mediating the basophil activation and pathogenesis of these disorders. Several reports have shown that healthy individuals, and patients with allergic disorders display IgG autoantibodies to IgE and hence functional characterization of these anti-IgE IgG autoantibodies is critical. In general, anti-IgE IgG autoantibodies modulate basophil activation irrespective of allergen specificity by interacting with constant domains of IgE. Therefore, an ideal solution to prove the functions of such anti-IgE IgG autoantibodies would be to completely eliminate type I high affinity immunoglobulin E receptor (FcɛRI)-bound IgE from the surface of basophils and to demonstrate in an unequivocal manner the role of anti-IgE IgG autoantibodies. In line with previous reports, our data show that FcɛRI on peripheral blood basophils are almost saturated with IgE. Further, acetic acid buffer (pH 4) efficiently removes these FcɛRI-bound IgE. Although immediately following acetic acid-elution of IgE had no repercussion on the viability of basophils, following 24 hours culture with interleukin-3 (IL-3), the viability and yield of basophils were drastically reduced in acid-treated cells and had repercussion on the induction of activation markers. Lactic acid treatment on the other hand though had no adverse effects on the viability of basophils and IL-3-induced activation, it removed only a small fraction of the cell surface bound IgE. Thus, our results show that acid buffers could be used for the elution of FcɛRI-bound IgE on the basophil surface for the biochemical characterization of IgE antibodies or for the immediate use of basophils to determine their sensitivity to undergo degranulation by specific allergens. However, these methods are not utile for the functional assays of basophils that require longer duration of culture and entire removal of surface IgE to validate the role of anti-IgE IgG autoantibodies that interact with FcɛRI-bound IgE irrespective of allergen specificity.

Identifiants

pubmed: 31941161
pii: ijms21020510
doi: 10.3390/ijms21020510
pmc: PMC7014331
pii:
doi:

Substances chimiques

Receptors, IgE 0
Immunoglobulin E 37341-29-0
Acetic Acid Q40Q9N063P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-19-CE17-0021 (BASIN)

Déclaration de conflit d'intérêts

The work is supported in part by research grant from CSL Behring, Switzerland. The funder has no role in the design of the study. The authors have no other conflicts of interest and sponsors.

Références

Int Immunol. 2008 Sep;20(9):1201-9
pubmed: 18632726
Acta Derm Venereol. 2002;82(5):335-40
pubmed: 12430731
J Allergy Clin Immunol. 2002 May;109(5):817-23
pubmed: 11994706
FASEB J. 2001 Oct;15(12):2268-74
pubmed: 11641254
J Allergy Clin Immunol. 2015 Dec;136(6):1636-1644
pubmed: 25962901
J Allergy Clin Immunol. 2018 Apr;141(4):1476-1479.e6
pubmed: 29208546
Cell Mol Immunol. 2019 Dec 4;:
pubmed: 31797906
Haematologica. 2017 Jun;102(6):e233-e237
pubmed: 28209657
J Allergy Clin Immunol. 1993 Feb;91(2):605-15
pubmed: 7679683
J Allergy Clin Immunol. 2014 Dec;134(6):1394-1401.e4
pubmed: 25112697
Sci Immunol. 2018 May 25;3(23):
pubmed: 29802207
J Clin Invest. 1995 Dec;96(6):2606-12
pubmed: 8675625
Allergol Int. 2019 Jul;68(3):342-351
pubmed: 30803853
Inflamm Res. 2009 Nov;58(11):737-45
pubmed: 19669619
Curr Opin Immunol. 2018 Oct;54:86-92
pubmed: 29986302
Nat Rev Rheumatol. 2015 Mar;11(3):129-31
pubmed: 25422004
Nat Immunol. 2016 Feb;17(2):196-203
pubmed: 26692173
J Allergy Clin Immunol. 2018 Aug;142(2):370-380
pubmed: 29247714
Allergy. 1995 Jan;50(1):72-7
pubmed: 7741191
J Allergy Clin Immunol. 1991 Nov;88(5):793-801
pubmed: 1955638
Clin Exp Immunol. 1984 Nov;58(2):348-56
pubmed: 6388923
J Clin Invest. 1978 Jul;62(1):176-81
pubmed: 659631
J Immunol. 1974 Mar;112(3):1078-84
pubmed: 4130108
J Clin Invest. 2014 Mar;124(3):1187-98
pubmed: 24569373
Clin Exp Allergy. 1994 Mar;24(3):270-5
pubmed: 7516815
Nat Med. 2010 Jun;16(6):701-7
pubmed: 20512127
Int Arch Allergy Appl Immunol. 1989;90(4):414-6
pubmed: 2693362
Arthritis Rheum. 1988 Aug;31(8):1000-6
pubmed: 3408506
Eur J Immunol. 1992 Aug;22(8):2025-32
pubmed: 1639103
Blood. 2008 Nov 15;112(10):3949-58
pubmed: 18768389
N Engl J Med. 1993 Jun 3;328(22):1599-604
pubmed: 7683772
Nat Immunol. 2011 Jun;12(6):527-35
pubmed: 21552267
Cell Res. 2016 Mar;26(3):271-2
pubmed: 26794873
J Allergy Clin Immunol. 2019 Mar;143(3):1100-1107.e11
pubmed: 29859965
Antibodies (Basel). 2019 Feb 22;8(1):
pubmed: 31544825
J Allergy Clin Immunol. 2019 Aug;144(2):524-535.e8
pubmed: 30529242
Nat Rev Immunol. 2013 May;13(5):362-75
pubmed: 23558889
Immunology. 2002 Nov;107(3):306-15
pubmed: 12423306
J Allergy Clin Immunol. 1990 Jul;86(1):73-81
pubmed: 1695233
Int J Mol Sci. 2018 Dec 22;20(1):
pubmed: 30583496
Int Immunol. 2017 Dec 30;29(11):491-498
pubmed: 28666326
Nat Rev Immunol. 2002 Oct;2(10):773-86
pubmed: 12360215
Int Arch Allergy Appl Immunol. 1985;76(3):237-42
pubmed: 3871737
Allergy. 1995 Mar;50(3):243-8
pubmed: 7545880
Eur J Immunol. 2012 Oct;42(10):2544-50
pubmed: 23042651
Nat Commun. 2013;4:2847
pubmed: 24284909
N Engl J Med. 2010 Sep 9;363(11):1080-2
pubmed: 20825323
Open Allergy J. 2010;3:91-101
pubmed: 25018787
Int Arch Allergy Appl Immunol. 1991;95(2-3):102-8
pubmed: 1718904
J Immunol. 1983 Oct;131(4):1949-53
pubmed: 6194222
Immunol Rev. 2011 Jul;242(1):144-60
pubmed: 21682743
Nat Commun. 2018 Feb 20;9(1):725
pubmed: 29463843
J Immunol. 1998 Feb 15;160(4):1957-64
pubmed: 9469459
J Immunol. 2019 Jun 15;202(12):3514-3523
pubmed: 31068389

Auteurs

Caroline Galeotti (C)

Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, F-75006, France.
Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires Rares et des Amyloses, CHU de Bicêtre, le Kremlin Bicêtre, F-94270 Paris, France.

Anupama Karnam (A)

Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, F-75006, France.

Mrinmoy Das (M)

Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, F-75006, France.

Srini V Kaveri (SV)

Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, F-75006, France.
Université Paris Descartes, Sorbonne Paris Cité, F-75006 Paris, France.

Jagadeesh Bayry (J)

Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, F-75006, France.
Université Paris Descartes, Sorbonne Paris Cité, F-75006 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH